ArticleJournal of cancer research and clinical oncology2018
Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database.
Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.Molecular oncology · 2019Trial
- Multi-Modal Prehabilitation in Thoracic Surgery: From Basic Concepts to Practical Modalities.Journal of clinical medicine · 2024Review
- The value of folate receptor-positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics.The clinical respiratory journal · 2023Article
- Estimating disease incidence rates and transition probabilities in elderly patients using multi-state models: a case study in fragility fracture using a Bayesian approach.BMC medical research methodology · 2023Article
- Construction and validation of a nomogram based on N6-Methylandenosine-related lncRNAs for predicting the prognosis of non-small cell lung cancer patients.Cancer medicine · 2023Article
- Older patients more likely to die from cancer-related diseases than younger with stage IA non-small cell lung cancer: a SEER database analysis.Journal of thoracic disease · 2022Article
- Surrogate Markers for Pulmonary Hypertension May Inform Prognosis in Lung Cancer.American journal of respiratory and critical care medicine · 2021Article
- A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.BMC cancer · 2020Article
- Clinicopathological characteristics and prediction of cancer-specific survival in large cell lung cancer: a population-based study.Journal of thoracic disease · 2020Article
- MiR-191-5p inhibits lung adenocarcinoma by repressing SATB1 to inhibit Wnt pathway.Molecular genetics & genomic medicine · 2020Article
- Marital Status and Survival in Osteosarcoma Patients: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Long non-coding RNA NORAD promotes the occurrence and development of non-small cell lung cancer by adsorbing MiR-656-3p.Molecular genetics & genomic medicine · 2019Article
- Treatment Patterns Among De Novo Metastatic Cancer Patients Who Died Within 1 Month of Diagnosis.JNCI cancer spectrum · 2019Article
- Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study.Cancer biology & medicine · 2019Article
- Nomogram Predicting Cause-Specific Mortality in Nonmetastatic Male Breast Cancer: A Competing Risk Analysis.Journal of Cancer · 2019Article
- HHIP overexpression inhibits the proliferation, migration and invasion of non-small cell lung cancer.PloS one · 2019Article
- Long non-coding RNA OIP5-AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR-378a-3p.Thoracic cancer · 2018Article
- Overexpression of long non-coding RNA KCNQ1OT1 is related to good prognosis via inhibiting cell proliferation in non-small cell lung cancer.Thoracic cancer · 2018Article
- Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.International journal of molecular sciences · 2018Review
- Factors Associated With Cause-specific Mortality in Older Patients With Advanced NSCLC Treated With PD-1 Inhibitors: A U.S. Population-based Cohort Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the probability of death (POD) from any causes by time after diagnosis of non-small cell lung cancer (NSCLC) and the factors associated with survival for NSCLC patients.
methodsA total of 202,914 patients with NSCLC from 2004 to 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The overall survival (OS) and lung cancer-specific survival (LCSS) were calculated and POD from any causes at different time periods after diagnosis was explored. The predictive factors for OS, LCSS and survival from non-lung cancer deaths were investigated using multivariate analysis with Cox proportional hazards regression and competing risk regression analysis.
resultsThe 5- and 10-year OS were 20.4% and 11.5%, accordingly that for LCSS were 25.5% and 18.4%, respectively. Lung cancer contributed 88.3% (n = 128,402) of the deaths. The POD from lung cancer decreased with time after diagnosis. In multivariate analysis, advanced age and advanced stage of NSCLC were associated with decreased OS and LCSS. Comparing to no surgery, any kind of resection conferred lower risk of death from lung cancer and higher risk of dying from non-lung cancer conditions except lobectomy or bilobectomy, which was associated with lower risk of death from both lung cancer and non-lung cancer conditions.
conclusionsMost of the patients with NSCLC died from lung cancer. Rational surveillance and treatment policies should be made for them. Early stage and lobectomy or bilobectomy were associated with improved OS and LCSS. It is reasonable to focus on early detection and optimal surgical treatment for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.